176 related articles for article (PubMed ID: 37915584)
1. Case report: Successful treatment of refractory membranous nephropathy with telitacicept.
Zhang L; Jin H; Wang D; Wang Y
Front Immunol; 2023; 14():1268929. PubMed ID: 37915584
[TBL] [Abstract][Full Text] [Related]
2. Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series.
Cortazar FB; Leaf DE; Owens CT; Laliberte K; Pendergraft WF; Niles JL
BMC Nephrol; 2017 Feb; 18(1):44. PubMed ID: 28143416
[TBL] [Abstract][Full Text] [Related]
3. Single-dose Rituximab Therapy for Refractory Idiopathic Membranous Nephropathy: A Single-center Experience.
Katsuno T; Ozaki T; Kim H; Kato N; Suzuki Y; Akiyama S; Ishimoto T; Kosugi T; Tsuboi N; Ito Y; Maruyama S
Intern Med; 2017; 56(13):1679-1686. PubMed ID: 28674357
[TBL] [Abstract][Full Text] [Related]
4. Rituximab In The Treatment Of Refractory Idiopathic Membranous Nephropathy In Pakistani Population.
Anjum N; Nabi Z; Alam MA
J Ayub Med Coll Abbottabad; 2019; 31(2):265-268. PubMed ID: 31094128
[TBL] [Abstract][Full Text] [Related]
5. Bortezomib as a Novel Approach to Early Recurrent Membranous Glomerulonephritis After Kidney Transplant Refractory to Combined Conventional Rituximab Therapy.
Barbari A; Chehadi R; Kfoury Assouf H; Kamel G; Jaafar M; Abdallah A; Rizk S; Masri M
Exp Clin Transplant; 2017 Jun; 15(3):350-354. PubMed ID: 28367758
[TBL] [Abstract][Full Text] [Related]
6. A case report of remission of refractory membranous nephropathy progressing to stage 4 chronic kidney disease using low-dose rituximab: A long-term follow-up.
Zhou XJ; Zhou FD; Wang SX; Zhao MH
Medicine (Baltimore); 2018 Jun; 97(25):e11184. PubMed ID: 29924035
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Ormond Disease and Idiopathic Membranous Glomerulonephritis by using Rituximab.
Dedinská I; Svetlík D; Adamicova K; Machalekova K; Makovicky P; Jezikova A; Laca L; Miklusica J; Galajda P; Mokan M
Iran J Kidney Dis; 2016 Sep; 10(5):332-335. PubMed ID: 27721233
[TBL] [Abstract][Full Text] [Related]
8. A Multicenter Randomized Controlled Trial of Rituximab versus Cyclosporine in the Treatment of Idiopathic Membranous Nephropathy (MENTOR).
Fervenza FC; Canetta PA; Barbour SJ; Lafayette RA; Rovin BH; Aslam N; Hladunewich MA; Irazabal MV; Sethi S; Gipson DS; Reich HN; Brenchley P; Kretzler M; Radhakrishnan J; Hebert LA; Gipson PE; Thomas LF; McCarthy ET; Appel GB; Jefferson JA; Eirin A; Lieske JC; Hogan MC; Greene EL; Dillon JJ; Leung N; Sedor JR; Rizk DV; Blumenthal SS; Lasic LB; Juncos LA; Green DF; Simon J; Sussman AN; Philibert D; Cattran DC;
Nephron; 2015; 130(3):159-68. PubMed ID: 26087670
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of efficacy of rituximab for membranous nephropathy: A systematic review and meta-analysis of 11 studies.
Ou JY; Chen YW; Li TL; Shan HZ; Cui S; Lai JJ; Xiao Y
Nephrol Ther; 2022 Apr; 18(2):104-112. PubMed ID: 35074299
[TBL] [Abstract][Full Text] [Related]
10. The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy.
Fernández-Juárez G; Rojas-Rivera J; Logt AV; Justino J; Sevillano A; Caravaca-Fontán F; Ávila A; Rabasco C; Cabello V; Varela A; Díez M; Martín-Reyes G; Diezhandino MG; Quintana LF; Agraz I; Gómez-Martino JR; Cao M; Rodríguez-Moreno A; Rivas B; Galeano C; Bonet J; Romera A; Shabaka A; Plaisier E; Espinosa M; Egido J; Segarra A; Lambeau G; Ronco P; Wetzels J; Praga M;
Kidney Int; 2021 Apr; 99(4):986-998. PubMed ID: 33166580
[TBL] [Abstract][Full Text] [Related]
11. Combination of Rituximab, Low-Dose Cyclophosphamide, and Prednisone for Primary Membranous Nephropathy: A Case Series With Extended Follow Up.
Zonozi R; Laliberte K; Huizenga NR; Rosenthal JK; Jeyabalan A; Collins AB; Cortazar FB; Niles JL
Am J Kidney Dis; 2021 Dec; 78(6):793-803. PubMed ID: 34174365
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological features and outcome in elderly patients with idiopathic membranous nephropathy.
Liang J; Hao W; Xia F; Zhao Z; Wu Y; Yu F; Hu W; Fang X; Liu W
Ren Fail; 2023 Dec; 45(1):2212081. PubMed ID: 37194712
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis.
Lu W; Gong S; Li J; Luo H; Wang Y
Medicine (Baltimore); 2020 Apr; 99(16):e19804. PubMed ID: 32311997
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the efficacy and safety of tacrolimus monotherapy and cyclophosphamide combined with glucocorticoid in the treatment of adult primary membranous nephropathy: protocol of a multicenter, randomized, controlled, open study.
Chen S; Ren S; Wang AY; Tran H; Li Z; Cheng X; Liu M; Li G; Wang L; Hong D
Trials; 2020 Feb; 21(1):219. PubMed ID: 32093742
[TBL] [Abstract][Full Text] [Related]
15. Idiopathic membranous nephropathy in children treated with rituximab: report of two cases.
Malatesta-Muncher R; Eldin KW; Beck LH; Michael M
Pediatr Nephrol; 2018 Jun; 33(6):1089-1092. PubMed ID: 29546599
[TBL] [Abstract][Full Text] [Related]
16. Immunosuppression therapy for idiopathic membranous nephropathy: systematic review with network meta-analysis.
Bose B; Chung EYM; Hong R; Strippoli GFM; Johnson DW; Yang WL; Badve SV; Palmer SC
J Nephrol; 2022 May; 35(4):1159-1170. PubMed ID: 35199314
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of low or heavy rituximab‑based protocols and comparison with seven regimens in idiopathic membranous nephropathy: a systematic review and network meta-analysis.
Chen M; Zhang X; Xiong Y; Xu G
Int Urol Nephrol; 2023 Mar; 55(3):641-651. PubMed ID: 36161550
[TBL] [Abstract][Full Text] [Related]
18. Remission of Refractory Membranous Nephropathy by Low-dose Rituximab: A Case Report.
Wang XP; Hu ZX; Guo DY; Tao Y
Chin Med J (Engl); 2016 Apr; 129(7):871-3. PubMed ID: 26996486
[No Abstract] [Full Text] [Related]
19. [Membranous nephropathy: New insights in therapeutic approach].
Dahan K
Nephrol Ther; 2017 Apr; 13 Suppl 1():S83-S87. PubMed ID: 28577748
[TBL] [Abstract][Full Text] [Related]
20. Low-dose Rituximab Monotherapy or in Combination with Tacrolimus Is Effective in Primary Membranous Nephropathy.
Pathak V; Venkatesan M; Regunathan-Shenk R
Kidney360; 2021 Feb; 2(2):336-338. PubMed ID: 35373023
[No Abstract] [Full Text] [Related]
[Next] [New Search]
